GoodRx price target lowered to $8 from $9 at Wells Fargo

Wells Fargo lowered the firm’s price target on GoodRx (GDRX) to $8 from $9 and keeps an Overweight rating on the shares. The firm says that while some end market noise persists, GoodRx appears to be stabilizing fundamentals and showing consistency across the enterprise. Wells notes some growth initiatives pan out slower than expected, but risk/reward feels balanced to the upside.